Characteristics of AA patients longitudinally studied
Patient no. . | Therapy drug . | Response . |
|---|---|---|
| 29 | rATG | Partial + |
| 31 | hATG/CsA | + |
| 33 | hATG/CsA | + |
| 39 | CsA | + |
| 40 | h+rATG (2×) | – |
| 41* | Anti-IL2 Ab | + |
| 42 | hATG/CsA | + |
| 45* | rATG | – |
| 46 | hATG | + |
| 47* | rATG/CsA | + |
| 48* | rATG | Partial + |
Patient no. . | Therapy drug . | Response . |
|---|---|---|
| 29 | rATG | Partial + |
| 31 | hATG/CsA | + |
| 33 | hATG/CsA | + |
| 39 | CsA | + |
| 40 | h+rATG (2×) | – |
| 41* | Anti-IL2 Ab | + |
| 42 | hATG/CsA | + |
| 45* | rATG | – |
| 46 | hATG | + |
| 47* | rATG/CsA | + |
| 48* | rATG | Partial + |
rATG indicates rabbit antithymocyte globulin; –, no response; hATG, human antithymocyte globulin; +, response to therapy; CsA, cyclosporin A; and partial +, partial response to therapy
These patients were studied only by VB flow cytometry